Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity

Ortiz-Bonilla, Carlos; Uccello, Taylor P.; Gerber, Scott A.; Lord, Edith M.; Messing, Edward M.; Lee, Yi-Fen

doi:10.3390/ijms23062904

Cited by 7 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ortiz-Bonilla CJ et al [ 182 ] observed that priming with bladder cancer-derived TEV prevented tumor growth in mice. Pro-inflammatory factors were shown to be enriched in TEV using cytokine array analyses.…”

Section: Ev-mediated Immune Activationmentioning

confidence: 99%

Extracellular Vesicles and Their Roles in the Tumor Immune Microenvironment

Reale

Khong

Spencer

2022

JCM

View full text Add to dashboard Cite

Tumor cells actively incorporate molecules (e.g., proteins, lipids, RNA) into particles named extracellular vesicles (EVs). Several groups have demonstrated that EVs can be transferred to target (recipient) cells, making EVs an important means of intercellular communication. Indeed, EVs are able to modulate the functions of target cells by reprogramming signaling pathways. In a cancer context, EVs promote the formation of a supportive tumor microenvironment (TME) and (pre)metastatic niches. Recent studies have revealed that immune cells, tumor cells and their secretome, including EVs, promote changes in the TME and immunosuppressive functions of immune cells (e.g., natural killer, dendritic cells, T and B cells, monocytes, macrophages) that allow tumor cells to establish and propagate. Despite the growing knowledge on EVs and on their roles in cancer and as modulators of the immune response/escape, the translation into clinical practice remains in its early stages, hence requiring improved translational research in the EVs field. Here, we comprehensively review the current knowledge and most recent research on the roles of EVs in tumor immune evasion and immunosuppression in both solid tumors and hematological malignancies. We also highlight the clinical utility of EV-mediated immunosuppression targeting and EV-engineering. Importantly, we discuss the controversial role of EVs in cancer biology, current limitations and future perspectives to further the EV knowledge in clinical practice.

show abstract

Section: Ev-mediated Immune Activationmentioning

confidence: 99%

Extracellular Vesicles and Their Roles in the Tumor Immune Microenvironment

Reale

Khong

Spencer

2022

JCM

View full text Add to dashboard Cite

show abstract

“… 18 Moreover, they can act as tumor vaccines, triggering a T cell-mediated anti-tumor immune response. 19 , 20 This helps in reducing the risk of tumor escape. In this study, TMPs loaded with doxorubicin (Dox-TMPs) were used to treat a mouse model of ascites HCC.…”

Section: Introductionmentioning

confidence: 99%

Drug-Loaded Tumor-Derived Microparticles Elicit CD8+ T Cell-Mediated Anti-Tumor Response in Hepatocellular Carcinoma

Chen,

Zhang,

Wang

et al. 2024

IJN

View full text Add to dashboard Cite

Background Hepatocellular Carcinoma (HCC) poses significant challenges due to limited effective treatments and high recurrence rates. Immunotherapy, a promising approach, faces obstacles in HCC patients due to T-cell exhaustion and immunosuppression within the tumor microenvironment. Methods Using doxorubicin-loaded tumor-derived microparticles (Dox-TMPs), the mice with H22 ascites model and subcutaneous tumors model were treated. Following the treatment, mice were re-challenged with H22 cells to compare the therapeutic effects and recurrence among different groups of mice, alongside examining the changes in the proportions of immune cells within the tumor microenvironment. Furthermore, Dox-TMPs were combined with anti-PD-1 to further validate their anti-tumor efficacy. In vitro studies using various liver cancer cell lines were conducted to verify the tumor-killing effects of Dox-TMPs. Additionally, CD8+ T cells from the abdominal cavity of tumor-free mice were co-cultured with H22 cells to confirm their specific tumor-killing abilities. Results Dox-TMPs demonstrate effective anti-tumor effects both in vitro and in vivo. In vivo, their effectiveness primarily involves enhancing CD8+ T cell infiltration, alleviating T cell immunosuppression, and improving the immune microenvironment to combat tumors. When used in combination with anti-PD-1, their anti-tumor effects are further enhanced. Moreover, some mice treated with Dox-TMPs developed anti-tumor immunity, displaying a self-specific T-cell immune response upon re-challenged with tumor cells. This suggests that Dox-TMPs also have the potential to act as a long-term immune response against tumor recurrence, indicating their capability as a tumor vaccine. Conclusion Dox-TMPs exhibit a dual role in liver cancer by regulating T cells within the tumor microenvironment, functioning both as an anti-tumor agent and a potential tumor vaccine.

show abstract

Development of a butyrate metabolism-related gene-based molecular subtypes and scoring system for predicting prognosis and immunotherapy response in bladder cancer

Yuan

Xiong

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity

Cited by 7 publications

References 48 publications

Extracellular Vesicles and Their Roles in the Tumor Immune Microenvironment

Extracellular Vesicles and Their Roles in the Tumor Immune Microenvironment

Drug-Loaded Tumor-Derived Microparticles Elicit CD8+ T Cell-Mediated Anti-Tumor Response in Hepatocellular Carcinoma

Development of a butyrate metabolism-related gene-based molecular subtypes and scoring system for predicting prognosis and immunotherapy response in bladder cancer

Contact Info

Product

Resources

About